Upregulated expression of LncRNA nicotinamide nucleotide transhydrogenase antisense RNA 1 is correlated with unfavorable clinical outcomes in cancers
Open Access
- 14 September 2020
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 20 (1) , 1-13
Abstract
Background: The nicotinamide nucleotide transhydrogenase antisense RNA 1 (NNT-AS1) is a long non-coding RNA aberrantly expressed in human malignancies. We aimed to analyze available data to evaluate the correlation between NNT-AS1 expression and cancer prognosis.Methods: Literature retrieval was performed by systematic searching related databases from inception to April 2, 2020. Studies regarding correlation between NNT-AS1 expression, survival outcomes and clinical characteristics of cancer patients were collected and pooled to calculate the the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (95% CIs).Results: Ten studies comprising 699 patients were included, all of which were conducted in China according to literature selection criteria. Overexpression of NNT-AS1 had a significant association with unfavorable overall survival (OS) (HR = 2.08, 95% CI: 1.84–2.36,P < 0.001). Stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis approach did not change the predictive value of NNT-AS1 on OS. Furthermore, elevated NNT-AS1 level had significant association with distant metastasis (DM) (OR = 2.45, 95% CI: 1.39–4.30), lymph node metastasis (LNM) (OR = 3.92, 95% CI: 1.35–11.41), TNM stage (OR = 4.25, 95% CI: 1.71–10.56), and vascular invasion (OR = 3.98, 95% CI: 2.06–7.71), but was not associated with age and gender. The TCGA dataset further consistently showed that the NNT-AS1 expression was associated with poor OS and disease-free survival.Conclusions: High expression of NNT-AS1 is associated with unfavorable survival outcomes and poor clinicopathologic characteristics. However, large-cohort data and geographical studies are still needed to further validate the prognostic value of NNT-AS1 in cancers.Keywords
All Related Versions
Funding Information
- National Natural Science Foundation of China (81902745)
- Natural Science Foundation of Hunan Province (2018JJ3716)
- Central South University Innovative Program for Undergraduates (20190034020002)
This publication has 37 references indexed in Scilit:
- Long non‑coding RNA NNT‑AS1 contributes to cell proliferation, metastasis and apoptosis in human ovarian cancerOncology Letters, 2018
- Overexpression of Long Non-Coding RNA NNT-AS1 Correlates with Tumor Progression and Poor Prognosis in OsteosarcomaCellular Physiology and Biochemistry, 2018
- Sex disparity in cancer: roles of microRNAs and related functional playersCell Death & Differentiation, 2018
- The Value of lncRNA NEAT1 as a Prognostic Factor for Survival of Cancer Outcome: A Meta-AnalysisScientific Reports, 2017
- Long noncoding RNA NNT-AS1 promotes hepatocellular carcinoma progression and metastasis through miR-363/CDK6 axisOncotarget, 2017
- Highly expressed long non-coding RNA NNT-AS1 promotes cell proliferation and invasion through Wnt/β-catenin signaling pathway in cervical cancerBiomedicine & Pharmacotherapy, 2017
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analysesNucleic Acids Research, 2017
- LncRNA HULC triggers autophagy via stabilizing Sirt1 and attenuates the chemosensitivity of HCC cellsOncogene, 2017
- The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mineLaboratory Investigation, 2013
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010